Clinical Trial Update: A Study to Assess BMS-986453 in Participants With Relapsed and/or Refractory Multiple Myeloma [Phase 1]

View source ↗

Summary

A Phase 1 clinical trial update for BMS-986453 in relapsed or refractory multiple myeloma. Sponsor Juno Therapeutics (a Bristol-Myers Squibb company) reports th…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• BMS-986453

Snippet

Sponsor: Juno Therapeutics, Inc., a Bristol-Myers Squibb Company | Conditions: Relapsed and/or Refractory Multiple Myeloma | Phase 1 | Status: RECRUITING